- Home
- NPCT vs ORIC Comparison
NPCT vs ORIC Comparison
Compare NPCT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- ORIC
- Stock Information
- Founded
- NPCT 2020
- ORIC 2014
- Country
- NPCT United States
- ORIC United States
- Employees
- NPCT N/A
- ORIC N/A
- Industry
- NPCT Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- ORIC Health Care
- Exchange
- NPCT Nasdaq
- ORIC Nasdaq
- Market Cap
- NPCT 306.8M
- ORIC 362.9M
- IPO Year
- NPCT N/A
- ORIC 2020
- Fundamental
- Price
- NPCT $11.22
- ORIC $10.31
- Analyst Decision
- NPCT
- ORIC Strong Buy
- Analyst Count
- NPCT 0
- ORIC 8
- Target Price
- NPCT N/A
- ORIC $18.83
- AVG Volume (30 Days)
- NPCT 107.1K
- ORIC 1.3M
- Earning Date
- NPCT 01-01-0001
- ORIC 08-11-2025
- Dividend Yield
- NPCT 9.82%
- ORIC N/A
- EPS Growth
- NPCT N/A
- ORIC N/A
- EPS
- NPCT N/A
- ORIC N/A
- Revenue
- NPCT N/A
- ORIC N/A
- Revenue This Year
- NPCT N/A
- ORIC N/A
- Revenue Next Year
- NPCT N/A
- ORIC N/A
- P/E Ratio
- NPCT N/A
- ORIC N/A
- Revenue Growth
- NPCT N/A
- ORIC N/A
- 52 Week Low
- NPCT $8.58
- ORIC $3.90
- 52 Week High
- NPCT $10.63
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- NPCT 70.75
- ORIC 71.78
- Support Level
- NPCT $10.55
- ORIC $8.85
- Resistance Level
- NPCT $10.75
- ORIC $10.99
- Average True Range (ATR)
- NPCT 0.10
- ORIC 0.69
- MACD
- NPCT 0.02
- ORIC 0.01
- Stochastic Oscillator
- NPCT 96.15
- ORIC 77.10
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.